Peter Doherty estimates that manufacturers should not have major failures to modify the pharmacy in case of mutation of the virus.
Australian virologist Peter Doherty, winner of the Nobel Prize in Physiology and Medicine in 1996, made sure that the vaccine’s efficacy runs counter to the coronavirus Sputnik V ‘looks fantastic’, suggesting that the manufacturers do not have major difficulties in modifying the drug. in case of mutation of the virus.
And declare a TASS, Doherty subrayó este jueves que Rusia tiene “a long history of the development of vacancies“. Additionally, consider the strategy of using the adenoviral vectors used in the pharmacy.
“By supuesto, if the virus changes significantly as a result of a mutation — because now it is in the process of transformation—, while the pharmacy ‘modifies’ a little, but will not be difficult,” the scientist, who obtains the gallbladder by its discoveries in the campus of the human immunological system, in particular its ability to identify infected cells with viruses.
The scientific review of The Lancet, one of the most prestigious medical ambitions, published this March, the results of the phase III results of the Sputnik V clinical trials, confirming that the antidote has a general efficacy of month 91%, does not cause serious secondary effects and is adequate for all ed groups.
If you like it, share it with your friends!